Spore.Bio funding news – Spore.Bio Raises $23Million in Series A Round Funding

The funding round also included Point 72 Ventures, 1st Kind Ventures (Peugeot Family Office), Station F, and Lord David Prior (ex-Chair NHS), along with continued support from existing investors LocalGlobe, No Label Ventures, and Famille C (Clarins Family Office).

This money will help Spore.Bio quickly bring its solution to the market and expand its team to address industry challenges more effectively.

The new funding comes after an $8.3 million pre-seed round in December 2023, bringing the total amount raised to $31.3 million. The company has not yet shared its valuation.

Amine Raji, CEO and co-founder of Spore.Bio said: “While AI is often associated with chatbots and LLMs, its niche applications are transforming specific industries, especially in science. We’re proud that our proprietary AI technology, developed in just one year, achieves what hasn’t been possible for two centuries. Our mission remains clear: using our technology to make every consumer product worldwide safe.”

Unlike big microbiology companies like Biomerieux and Biorad, which use molecular biology (PCR) and take 48 hours to get results, Spore.Bio has created a third-generation system that detects bacteria instantly using only light and is easy for users to operate.

The device uses advanced machine learning to measure bacteria levels in food, drinks, medicine, and cosmetics, notifying managers of any potential risks.

This cutting-edge device allows for immediate detection of pathogens directly on factory floors. By combining machine learning, light technology, and AI it can quickly identify bacterial levels in products within seconds.

Read also - Pixel Photonics funding news – Munster-based DeepTech Startup Pixel Photonics Secures €1 Million in Funding

This gives manufacturers real-time data, better tracking, and more transparency while reducing risks of cross-contamination and cutting costs. Most importantly, it helps manufacturers fix contamination issues before they become serious health problems.

Spore.Bio has expanded beyond food and drinks into the pharmaceutical and cosmetics industries, with over 200 factories interested in their technology, creating a waitlist for new installations.

The startup has also partnered with the Pasteur Institute, a leading microbiology organization, to strengthen its capabilities through access to their research and resources. Additionally, Spore.Bio has acquired Greentropism, a competitor that raised €3M, to benefit from its technical expertise and intellectual property.

Raffi Kamber, General Partner at Singular, said: “Originally developed for the Food and beverage sector, Spore.Bio is now reshaping microbiological detection in pharmaceuticals and cosmetics. With a founding team that blends research and industrial expertise, it is redefining speed, precision, and scalability—setting new standards. We are confident it will be a driving force in the future of integrated testing across industries and are excited to support and witness this transformation.”

About Spore.Bio

Spore.Bio was founded in 2023 by three entrepreneurs: Amine Raji (former Nestlé employee), Maxime Mistretta, and Mohamed Tazi (who sold his company Gymlib to EGYM). Spore.Bio is a deep tech startup that uses machine learning and microbiology to detect harmful bacteria in real-time at factories that make consumer goods. The team is supported by top scientists who specialize in microbiology, machine learning, optics, photonics, and chemometrics.